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Abstract
Background—Chronic congestive hepatopathy is known to cause hepatic fibrosis and portal
hypertension in patients post-Fontan operation for single ventricle palliation. The clinical
significance of these findings is not clear. We hypothesized that features of portal hypertension
would be significantly related to major adverse events.
Methods—A retrospective review of 73 adult and pediatric post-Fontan patients referred for a
liver evaluation from 2001-2011 was performed. The relationship between features of portal
hypertension (VAST score ≥2, 1 point each for Varices, Ascites, Splenomegaly or
Thrombocytopenia) and a major adverse event (death, need for transplant, or hepatocellular
carcinoma) was examined using logistic regression.
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Results—73 post-Fontan patients (30% female, 73% Caucasian, 66% systemic left ventricle
(SLV), mean age 24 ±11 years, mean interval from Fontan 17 ±6 years) were included in analysis.
Features of portal hypertension (VAST score ≥2) were present in 26 (36%), and there were 19
major adverse events: death (n=12), transplant (n=6), HCC (n=1). A significant relationship was
found between VAST score ≥2 and major adverse events (OR=9.8, 95% CI [2.9-32.7]). After
adjusting for time since Fontan, SLV, age, hemoglobin and type of failure, VAST score ≥2
remained significant (OR=9.1, 95% CI [1.4-57.6]).
Conclusion—Fontan patients with features of portal hypertension have a 9-fold increased risk
for a major adverse event. Therapies targeted to manage clinical manifestations of portal
hypertension, and early referral to heart transplant may help delay major adverse events. Future
prospective studies are needed to confirm these findings.
Keywords
Fontan; liver disease; features of portal hypertension; congenital heart disease; adult congenital
heart disease
Introduction
Over the last 40 years, the Fontan operation has become the standard of care for patients
with congenital heart disease consisting of single ventricle physiology. While the operation
improves oxygen saturation and short-term operative outcomes have improved substantially,
the long-term complications are becoming increasing recognized. In the largest series of
long-term follow up, including only the early operative survivors, 1 in 5 patients had died or
received a heart transplant at 20 years post Fontan[1]. Indeed, some authors have referred to
the physiology as the “failing Fontan[2].”
The mechanics of Fontan failure remain poorly understood. While clearly the failing
hemodynamics are related to having a single systemic ventricle with passive blood flow
through the lungs, the adult congenital patient with Fontan physiology has multi-system
organ dysfunction—particularly involving the liver—that contributes to the
pathophysiology[3].
Recent attention has focused on the pathology of the liver inherent to Fontan physiology that
is presumably related to post-sinusoidal increased venous pressure. Numerous series have
shown nodular changes and fibrosis that progress with time since the Fontan palliation[4, 5].
However, clinical markers of liver enzyme abnormalities, bilirubin, and even biopsy may
not capture the extent of liver dysfunction and to date have not been correlated with clinical
outcomes[6].
In this study, we examined a large group of both pediatric and adult Fontan patients to
evaluate the relationship of clinical features of portal hypertension to major adverse events
including hepatocellular carcinoma (HCC), need for transplant, or death.
Methods
Subjects
All children and adults palliated with a Fontan procedure and followed by Children’s
Healthcare of Atlanta or Emory Adult Congenital Heart Center between 2001-2011 who had
a hepatic evaluation were retrospectively reviewed (n=73). Approval was obtained from the
Emory University IRB prior to data collection. Patients were screened, but not excluded, for
known causes of hepatic injury (viral hepatitis or heavy alcohol use >2 drinks per day).
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Demographic, medical history, clinical, and imaging data at time of hepatic evaluation were
collected via chart review.
Measurements
The primary outcome was a major adverse event, defined as having one of the following:
death, heart transplant or listing for transplant, or HCC.
Hepatic imaging at the time of liver evaluation (MRI, CT, or abdominal ultrasound [US])
was reviewed. Data regarding nodular contour (yes or no), dilated hepatic veins (yes or no),
texture (heterogenous or homogenous), splenomegaly (yes or no), and presence of varices
including esophageal or gastric (yes or no) were collected. In case of discrepancy, order of
imaging preference was as follows: MRI>CT>US.
Features of portal hypertension were determined using the author-developed VAST score.
The score was calculated by the sum of clinical findings (Varices, Ascites, Splenomegaly,
and Thrombocytopenia [platelets <150]). Varices were counted if present on any imaging
modality. Ascites was considered present if seen either on imaging or clinical exam.
Splenomegaly was counted if measured >13 cm in maximal diameter on any imaging
modality. Scores ranged from 0 (no clinical findings) to 4 (all clinical findings present). A
VAST score ≥2 was considered having features of portal hypertension.
Potential covariates of major adverse health outcomes and portal hypertension included
demographics (gender, age and race), medical history, and cardiac variables. Medical history
data included time since the Fontan operation (years), comorbidities (diabetes, hypertension,
dyslipidemia, protein losing enteropathy, pulmonary arterial hypertension, arrhythmia), type
of congenital heart disease (hypoplastic left heart syndrome, tricuspid atresia, double inlet
left ventricle, pulmonary atresia/hypoplastic right heart, double outlet right ventricle,
transposition of the great vessels, or other), type of Fontan (atriopulmonary, lateral tunnel, or
extracardiac), and systemic ventricle (left or right).
The electrocardiogram was analyzed for rhythm and QRS duration. Echocardiographic data
included the following: systemic ventricular function (normal/mild decreased vs. moderate/
severely decreased), atrioventricular valve regurgitation (none/mild vs. moderate/severe),
and IVC diameter (cm) measured at end exhalation. Ventricular function was determined by
echocardiography using subjective assessment, Simpson’s method, or triplane three-
dimensional reconstruction in multiple views.
Patients were classified as type of failure as follows: no failure (normal/mildly decreased
ventricular function, no diuretics), heart failure (moderate/severely decreased ventricular
function, on ≥1 diuretics) or Fontan failure (normal/mildly decreased function, on ≥1
diuretics).
Other clinical data included medications at time of liver evaluation, body mass index (BMI,
kg/m2) and laboratory values (sodium, creatinine, total bilirubin, total protein, alkaline
phosphatase (ALP), asparate aminotransferase (AST), alanine aminotransferase (ALT),
hemoglobin, platelet count, and hepatitis serologies for A, B and C).
Statistical Methods
Differences between groups were determined using t-test and chi-square, and Fisher’s exact
or Wilcoxon where appropriate. Bivariate correlations were used to determine any
significant relationships between study variables and major adverse events, and between
study variables and portal hypertension to determine potential confounders. Univariate and
multivariate logistic regression were used to statistically evaluate the relationship between
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features of portal hypertension (VAST score ≥2) and major adverse events. As input to
stepwise regression, variables were chosen that were either significant in univariate analysis
at the p<0.20 level or chosen based on predictors of adverse events. In the final model, we
included time since Fontan (years), age, and type of failure (heart failure vs. Fontan failure
vs. no failure), all of which were chosen for univariate significance. Hemoglobin as a
surrogate for cyanosis and systemic ventricle (left vs. right) were added to the model to
account for suspected risk factors for outcomes. The data was analyzed using SAS 9.3, at an
alpha level of 0.05.
Results
A total of 73 adult and pediatric Fontan patients were included in the analysis. The mean age
of the cohort was 24 years (±11, range 9-54) and mean time since the Fontan operation was
16.9 years (±6.3 years). The majority were male (n=51, 70%), Caucasian (n=53, 73%), and
had a systemic left ventricle (SLV, n=48, 66%). Twenty-six of the patients had a classic
atriopulmonary Fontan as the primary procedure, 38 had a lateral tunnel Fontan, and 9 had
an extracardiac Fontan. Six of the patients with an atriopulmonary Fontan had undergone a
Fontan conversion to a lateral tunnel.
Anatomic features of the cohort were as follows: tricuspid atresia (n=27), hypoplastic left
heart syndrome (n=13), double outlet right ventricle (n=10), double inlet left ventricle
(n=10), pulmonary atresia/hypoplastic right heart (n=10) or other (n=3).
Of the entire cohort, 14 patients (19.2%) had varices, 25 (35.6%) had ascites, 23 (31.9%)
had splenomegaly, and 32 (44.4%) had a platelet count <150K at the time of liver
evaluation. Twenty-six patients (36%) had 2 or more of these findings. Nineteen patients
(26%) experienced a major adverse event, none of which occurred in the pediatric cohort.
Twelve patients died: 3 from congestive heart failure, 4 from Fontan failure with liver
disease, 2 sudden deaths, and 3 related to surgical interventions including one patient 1 year
following heart transplant, and 2 following revision to total cavopulmonary connection. A
total of six patients were either listed for heart transplant or received transplant, and 1
patient developed HCC.
When compared to the 54 patients without a major adverse event, the group that experienced
a major adverse event (death, need for transplant or HCC) was significantly more likely to
have features consistent with portal hypertension defined as a VAST score ≥2 (OR=9.8,
95% CI [2.9-32.7], FIGURE 1). Those who suffered an event were significantly older (33.2
vs. 21.9 years, p<.0001), further out from Fontan operation (21.6 vs. 15.2 years, p<.0001)
and more likely to show echocardiographic signs of dysfunction (decreased systemic
ventricular function 47.4% vs. 7.7%, p=.0001) and elevated central venous pressure (IVC
diameter 2.3 vs. 1.9 cm, p=.005) as compared to those without an event (TABLE 1).
Adjusting for BSA, however, IVC diameter was no longer significantly related to adverse
events (p=0.09). The event group had greater QRS prolongation compared to those without
an event (128 vs. 105 ms, p=.006).
Other significant variables in univariate analysis that were different between the two groups
are depicted in TABLES 1-3 and included type of Fontan, presence of pacemaker,
nodularity on liver imaging, medication usage, and laboratory values including sodium,
creatinine, total protein, albumin, ALP. The event group was also more likely to be taking
amiodarone, warfarin, ACE-inhibitors and multiple diuretics at the time of liver evaluation.
In multivariate analysis, adjusting for time since Fontan, SLV, age, hemoglobin level, and
type of failure, features of portal hypertension remained significantly related to major
adverse events. Patients with VAST ≥2 had 9 times the odds of experiencing an adverse
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event compared to those with VAST <2 (OR=9.1, 95% CI [1.4-57.6]). Type of failure was
also significantly related to major adverse events. Compared to patients with Fontan failure,
patients with heart failure had 19 times the odds of experiencing a major adverse event
(OR=19.7, 95% CI [1.8-210.9]. The other variables tested in the model were not statistically
significant FIGURE 2. The multivariate analysis was repeated excluding the two patients
who died post-operatively following Fontan conversion, but this did not change the findings.
VAST ≥2 remained significantly related to adverse events (OR 15.7 CI [1.8-135.1].
Among the groups of failure type, 7 (78%) of the 9 patients classified as heart failure with
moderate to severe dysfunction experienced a major event. 25% of those with Fontan failure
had a major event, and 15.8% of those patients without any form of failure experienced a
major event (p=<.001) TABLE 4.
Discussion
The Fontan operation, first described in 1971, is the final step in the surgical palliation of
congenital cardiac patients with a single functional ventricle[7]. The procedure creates non-
pulsatile flow via direct connection of the vena cavae to the pulmonary arteries and results in
an immediate elevation in central venous (and thus hepatic venous) pressure.
Liver dysfunction among Fontan patients is prevalent and may be a significant cause of late
morbidity and mortality in adults with congenital heart disease[3, 4]. To date, liver
dysfunction has not been shown to correlate with clinical outcomes[6]. Among adults with
Fontan physiology, non-invasive studies indicate that 57-90% show signs of liver
dysfunction[8, 9]. In two invasive studies with biopsy, 17/18 and 7/12 adults had some form
of cirrhosis[10, 11]. Early studies focused on laboratory data, showing mild abnormalities in
coagulation profiles and liver enzymes. More recent studies have shown various
radiographic changes, including surface nodularity, hepatic vein dilatation, increased
paranchymal echogenecity, and the presence of collateral vessels[4, 12]. The extent of
fibrosis, however, does not typically correlate with traditional liver function tests[6].
Histological and morphological changes may occur with only mildly abnormal coagulation
and liver profiles and no clinical symptoms[11].
In this study, we examined a group of adult and pediatric Fontan patients referred for hepatic
evaluation and determined predictors of major adverse events. As expected, on univariate
analysis those with a major adverse event were more likely than controls to have moderate
to severely decreased systemic ventricular function, longer QRS duration, older age at the
time of event and longer duration since the time of Fontan. The group with events was sicker
overall, as evidenced by the higher proportion with a pacemaker, use of Vaughn-Williams
class III antiarrhythmics, and requiring diuretics. Laboratory values including sodium,
creatinine, total protein, albumin and alkaline phosphatase were statistically different
between groups, but were within the normal range for lab values and have limited clinical
meaning.
There was a difference between the groups in the proportion of atriopulmonary Fontans,
which comprised 68% of the event group as compared to 24% of the non-event group.
Patients with an event were all adults and statistically older and further out from the time of
Fontan surgery as compared to those with non-events, thus historically more likely to have a
classic atriopulmonary Fontan. Previous work has suggested a number of potential
advantages to Fontan conversion[13]. Although 6 of the patients underwent Fontan
conversion, they were analyzed based on their original Fontan operation and thus no
conclusions can be drawn regarding any potential advantage of conversion.
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Definition of portal hypertension
We defined features of portal hypertension as having a VAST score of ≥2 of the following:
Varices, Ascites, Splenomegaly, or Thrombocytopenia (each accounting for one point). This
author-derived scoring system was used to address the challenge of characterizing liver
disease in Fontan patients. The standard for evaluation of intrahepatic portal hypertension in
patients with cirrhosis is assessment of the hepatic venous pressure gradient, where >10
mmHg is considered significant[14]. With regard to the definition of portal hypertension in
the Fontan population, a gradient across the sinusoidal bed is not required to have portal
hypertension[11]. Wedge pressure gradient is reflective of portal hypertension in sinusoidal
disease, but not applicable in post sinusoidal hypertension (elevated hepatic venous
pressures). The only true measure of portal venous pressure in that instance is direct
measurement of the portal vein pressure, which is clinically not done with any regularity.
Therefore surrogates were used for the clinical definition.
While other non-invasive scoring systems do exist, to our knowledge none have been used
in this patient population. Each of the features of the VAST score has been associated with
portal hypertension, and in our study was different between the event vs. non-event groups
(while total platelet count was different between the groups, the dichotomized variable of
<150 only trended toward significance; platelets <150 has been considered a marker for
portal hypertension)[14]. In restricting the definition to ≥2 VAST features, we aimed to
eliminate false positives.
Similar to pulmonary hypertension, which has been divided into groupings including
pulmonary arterial hypertension and pulmonary venous hypertension, portal hypertension
can also be grouped by anatomic level of the obstruction and may occur at multiple sites.
Post-hepatic obstruction (post-sinusoidal), as occurs anatomically in the Budd-Chiari
syndrome and physiologically in both right heart failure and the Fontan circulation, creates a
picture of congestive hepatopathy. Long-standing congestive hepatopathy has been shown to
lead to hepatic fibrosis, and ultimately cirrhosis[15]. The development of hepatic fibrosis
may create intrahepatic pre-sinusoidal fibrosis, further obstructing portal venous inflow.
These changes have been demonstrated in biopsy and postmortem studies of the liver in
Fontan patients[10, 11]. In the late Fontan circulation in which clinical deterioration is noted
with or without ventricular failure, the physiologic and neurohormonal changes that occur in
the setting of elevated portal venous pressures likely contribute to circulatory dysfunction,
renal hypoperfusion, and clinical deterioration.
Multivariate model
In the multivariate model, the strongest predictor of a major adverse event was heart failure
as evidenced by moderate to severe dysfunction and requiring diuretics. There were only 9
patients with this degree of dysfunction, but they were 19 times more likely than patients
with preserved ventricular function to experience an event.
Perhaps the more surprising finding is in regard to the influence of features of portal
hypertension on major adverse events. Fontan patients with a VAST score of ≥2 had a 9-fold
increased risk of experiencing a major adverse event as compared to those without. Over
half of the patients with a major adverse event had preserved systolic function of the
systemic ventricle, and the development of portal hypertension features may partially
explain this phenomenon. Among those patients defined as Fontan failure with preserved
ventricular function, 25% experienced an event. A VAST score ≥2 was a stronger predictor
on multivariate analysis than age of the patient, morphologic left ventricle, or time since
Fontan operation, criteria that might logically be associated with adverse outcomes in this
Elder et al. Page 6
Int J Cardiol. Author manuscript; available in PMC 2014 October 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
group. These findings suggest that therapies may need to be tailored to the patient’s clinical
situation and risk factors late after Fontan palliation.
The progressive liver impairment seen in many adult Fontan patients may be caused by
chronic elevation of central venous pressure and hepatic ischemia related to chronic low
cardiac output[2]. In non-congenital heart failure patients, cirrhotic cardiomyopathy has
been recognized as a cause for heart failure associated with high cardiac output and low
systemic vascular resistance[16]. While patients with cirrhotic cardiomyopathy share
similarities with Fontan patients, there are important differences. Adults with Fontan
physiology share a low systemic vascular resistance, but they have a relatively reduced
cardiac index as compared to non-congenital patients (unpublished data). The additional
insult of substantial hepatic injury could create a vicious feed-back loop and worsen cardiac
function, effect pulmonary circulation (i.e. hepatopulmonary syndrome or portopulmonary
hypertension), and further lower systemic vascular resistance with a limited ability to
augment cardiac output. This could ultimately lead to poor perfusion of many organs, in
particular the heart, kidneys, and liver.
Clinical implications
The significance of considering the physiologic consequences of elevated portal pressures in
the Fontan circulation becomes relevant when considering the common occurrence of late
clinical decompensation (“failing Fontan”) in the setting of normal ventricular function and
“good Fontan pressures.” A better understanding of the physiologic changes that occur in
the Fontan circulation will enable development of therapies to address the multifactorial
physiologic changes leading to circulatory dysfunction.
In addition to better treating the late deterioration, an improved understanding the role of
congestive hepatopathy and elevated portal pressures may have implications for preventing
or delaying this late clinical deterioration. If elevated central venous pressure is causative of
late hepatic fibrosis and cirrhosis, and features of portal hypertension are associated with
major adverse events, this may have implications for the timing of the Fontan procedure.
Previous work has shown in those with a Fontan physiology, one important risk factor for
liver dysfunction is timing since Fontan, with risk increasing at 5 and 10 years post-
operation[11]. If these late hepatic complications are based on time from surgery, and they
limit life-expectancy, one could suggest delay in initial Fontan palliation when possible.
Adults living today typically had the Fontan procedure as much as 10-20 years later than
what occurs in contemporary clinical practice. Thus, if liver dysfunction is directly related to
time since Fontan, the late morbidity and mortality in this population may begin to occur
earlier, perhaps even in childhood. In our study, none of the major adverse events occurred
in patients under 20 years of age. No patient less than 15 years old had features of portal
hypertension, but there were 5 between the ages of 16-19 years that had a VAST score ≥2.
Although time since Fontan was not significantly associated with major events in the
multivariate analysis, this study may be underpowered to detect such a relationship.
The relationship of portal hypertension and poor clinical outcomes has a profound impact on
how adult patients with Fontan physiology are managed. Cardiologists caring for older
Fontan patients need to be aware of and screen for occult liver disease, evaluating for
features of portal hypertension. To date, laboratory screening for liver enzyme abnormalities
and even biopsy have not been correlated with clinical outcomes, suggesting synthetic
function of the liver is relatively preserved. Given hepatic dysfunction and fibrosis after
Fontan palliation, patients should be counseled to avoid hepatic toxins (e.g. alcohol) and
employ preventative strategies for liver health (e.g. hepatitis vaccination). Medication may
need to be tailored as the hemodynamic phenotype changes over time. For example, use of
systemic vasodilators—routinely employed to treat heart failure of other etiologies—could
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potentially worsen circulatory dysfunction in those with advanced liver disease, potentially
precipitating hepatorenal syndrome.
While cardiac transplant is a limited option for some failing adult Fontan patients, pre-
operative evaluation must define the extent of liver disease. A few Fontan patients have
gone on to combined heart and liver transplant, but data regarding outcomes is limited[17,
18]. Future efforts to manage this population should focus on tailoring therapy to the unique
physiology in this patient population.
Study Limitations
Our study has a number of potential limitations. It is retrospective in nature, and included a
selected, tertiary referral population with advanced symptoms. The results may not be as
applicable to a “well” Fontan population. The study group is small, and the results and
VAST score need to be validated in a larger population of Fontan patients. Features of the
VAST score are often late findings in portal hypertension and thus may not detect early
pathology in Fontan patients. Because of the small sample size, the multivariate model was
not able to account for each of the univariate predictors of outcomes. We attempted to
overcome this by creating a composite surrogate to incorporate univariate predictors by
examining heart failure, Fontan failure vs. no evidence of failure.
Conclusions
In Fontan patients with advanced symptoms, those with features of portal hypertension (a
VAST score ≥2) had a 9-fold increase in major adverse events including death, need for
transplant, or HCC. Poor systemic ventricular function, though uncommon, was also
significantly associated with events. Cardiologists need to be aware of the association of
portal hypertension and related circulatory dysfunction with adverse events and should tailor
medical therapy, including referral for cardiac transplantation, as appropriate.
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Figure 1. Comparison of major event by feature of portal hypertension (VAST≥2)
In univariate analysis, features of portal hypertension (VAST ≥2) were associated with a
9.8-fold increase (95% CI [2.9-32.7]) in risk of major adverse health outcomes.
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Figure 2. Odds Ratios and 95% CI for Multivariate Logistic Regression Analysis
In multivariate analysis, features of portal hypertension (Portal HTN) and heart failure (HF)
were significant predictors of major adverse events.
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Table 1
Variable Overall
n=73
No Event
n=54
Event
n=19 p-value
Demographics
Age (mean, SD) 24 (9-54) 21.9 (9.8) 33.2 (10.4) <0.0001
Female 22 (30.1%) 17 (31.5%) 5 (26.3%) 0.67
Caucasian 53 (72.6%) 37 (68.5%) 16 (84.2%) 0.64
Fontan Characteristics
Years Post-
Fontan (mean, SD) 16.9 (6.3) 15.2 (5.7) 21.6 (5.5) <0.0001
Left Ventricle 48(65.8%) 35 (64.8%) 13 (68.4%) 0.78
Type of Fontan
0.002
Atriopulmonary 26 (35.6%) 13 (24.1%) 13(68.4%)
Lateral Tunnel 38 (52.1%) 32 (59.3%) 6(31.6%)
Extracardiac 9 (12.3%) 9 (16.7%) 0 (0%)
Fontan Revision 6 (8.2%) 5 (9.3%) 1 (5.3%) 1
Pacemaker 24 (32.9%) 13 (24.1%) 11(57.9%) 0.007
QRS Duration msec
(n=51)
111.9
(27.7%) 105.2 (18.5) 128.0 (38.6) 0.04
Mod-severe decreased
function (n=71) 13 (18.3%) 4 (7.7%) 9 (47.4%) <0.0001
AV Regurgitation
 (Mod/Severe) (n=71) 12 (16.9%) 8 (15.4%) 4 (21.1%) 0.47
Hepatic Imaging (MRI/CT/US)
Nodular Contour 40 (63.5%) 26 (55.3%) 14 (82.4%) 0.05
Dilated Hepatic Veins 22 (34.9%) 17 (36.2%) 5 (29.4%) 0.62
Heterogeneous Texture 56 (88.9%) 40 (85.1%) 16 (84.2%) 0.67
AV = atrioventricular; SD = Standard deviation
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Table 2
Variable Overall
n=73
No Event
n=54
Event
n=19
p-value
Features of portal
hypertension 26 (35.6) 12 (22.2) 14 (73.7) <0.0001
Varices 14 (19.2) 4 (7.4) 10 (52.6) <0.0001
Ascites 25 (35.6) 13 (24.1) 12 (63.2) 0.004
Splenomegaly 23 (31.9) 11 (20.4) 12 (66.7) <0.001
Platelet Count < 150K 32 (44.4%) 21 (38.9) 11 (57.9) 0.18
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Table 3
Variable Overall
n=73
No Event
n=54
Event
n=19
p-value
Comorbidities
Arrhythmia 38 (52.1) 25 (46.3) 13 (72.2) 0.06
Hypertension 6 (8.2) 5 (9.3) 1 (5.6) 1
Diabetes 3 (4.1) 2 (3.7) 1 (5.6) 0.74
PLE 7 (9.6) 5 (9.3) 2 (11.1) 0.82
PAH 2 (2.7) 1 (1.9) 1 (5.6) 0.44
Dyslipidemia 1 (1.4) 0 (0) 1 (5.6) 0.25
Heavy Alcohol Use 1 (1.4) 1 (1.9) 0 (0) 1
Medications
ACEI or ARB 40 (55.6) 34 (63.0) 6 (33.3) 0.05
Beta-blocker 33 (45.8) 23 (42.6) 10 (55.6) 0.34
Coumadin 27 (37.5) 16 (29.6) 11 (61.1) 0.02
Amiodarone (n=41) 9 (23.1) 2 (9.1) 7 (41.2) 0.03
≥ 1 Diuretic 36 (50.0) 23 (42.6) 13 (72.2) 0.03
Digoxin 18 (25.0) 15 (27.8) 3 (16.7) 0.53
Lab Values*
Sodium 139.4 (2.9) 139.8 (2.6) 138.2 (3.6) 0.04
Hemoglobin 15.2 (1.8) 15.3 (1.6) 14.7 (2.3) 0.17
Creatinine .87 (.32) .81 (.22) 1.1 (.47) 0.046
Total Bilirubin 1.1 (.74) 1.0 (.76) 1.3 (.61) 0.14
Total Protein 7.5 (.86) 7.6 (.76) 6.9 (.95) 0.003
Albumin 4.3 (.73) 4.4 (.70) 3.8 (.62) 0.002
Alkaline phosphatase 141.5 (87.1) 156.1 (91.3) 97.9 (70.5) 0.002
AST 35.3 (16.9) 36.7 (14.2) 31.0 (23.0) 0.33
ALT 28.1 (13.7) 27.5 (13.5) 29.7 (14.7) 0.57
Platelets
179.2
(70.9) 189.7 (73.6) 149.7 (54.4) 0.03
Hepatitis B (n=60) 2 (2.8) 1 (2.3) 1 (7.1) 0.43
Hepatitis C (n=63) 0 0% 0% 1
*
= <3% of data missing
PLE = protein losing enteropathy, PAH = pulmonary arterial hypertension
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Table 4
Failure Type Total
n=71
No Event
n=52
Event
n=19
p-value
Heart Failure 9 2 7 (78%)
<.001
Fontan Failure 24 18 6 (25%)
No Failure 38 32 6 (16%)
Heart failure = moderate/severely decreased ventricular function, on ≥1 diuretics
Fontan failure = normal/mildly decreased function, on ≥1 diuretics
No failure = normal/mildly decreased ventricular function, no diuretics
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